{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:42:09Z","timestamp":1792575729015,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300958"],"award-info":[{"award-number":["32300958"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Guangdong Province of China","award":["2023A1515010489"],"award-info":[{"award-number":["2023A1515010489"]}]},{"name":"Shenzhen Fundamental Research Program, grant number","award":["20231120142637001"],"award-info":[{"award-number":["20231120142637001"]}]},{"name":"Science and Technology project of Shenzhen of China","award":["JCYJ20230807113016034"],"award-info":[{"award-number":["JCYJ20230807113016034"]}]},{"name":"Shenzhen Medical Research Funds","award":["A2303047"],"award-info":[{"award-number":["A2303047"]}]},{"name":"Shenzhen Medical Research Funds","award":["B2402048"],"award-info":[{"award-number":["B2402048"]}]},{"name":"Shenzhen Medical Research Funds","award":["A2303028"],"award-info":[{"award-number":["A2303028"]}]},{"name":"Guangdong Natural Science Foundation","award":["2025A1515011660"],"award-info":[{"award-number":["2025A1515011660"]}]},{"DOI":"10.13039\/100016588","name":"Shenzhen Research Institute, City University of Hong Kong","doi-asserted-by":"publisher","award":["A2403054"],"award-info":[{"award-number":["A2403054"]}],"id":[{"id":"10.13039\/100016588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016086","name":"Key Laboratory in Science and Technology Development Project of Suzhou","doi-asserted-by":"publisher","award":["JCYJ20240808182828002"],"award-info":[{"award-number":["JCYJ20240808182828002"]}],"id":[{"id":"10.13039\/100016086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent disorder characterized by excessive hepatic lipid accumulation, frequently progressing to steatohepatitis, fibrosis, and cirrhosis. Transcription factor EB (TFEB) coordinates lysosomal biogenesis, autophagy, and lipid catabolism, and therefore represents a potential therapeutic target; however, safe and direct strategies for selectively enhancing hepatic TFEB activity remain limited. Here, liver-targeted lipid nanoparticles (LNPs) were developed to deliver mRNAs encoding wild-type TFEB or the constitutively active TFEB S211A mutant, and their efficacy was evaluated in cellular and choline-deficient, L-amino acid-defined high-fat diet (CDAHFD)-induced mouse models of MASLD. LNP-mediated delivery increased hepatic TFEB expression, enhanced autophagic flux, and reprogrammed metabolic pathways toward fatty acid oxidation (e.g.,\n                    <jats:italic>CPT1A<\/jats:italic>\n                    and\n                    <jats:italic>ACOX1<\/jats:italic>\n                    ) while suppressing the expression of lipogenic genes (e.g.,\n                    <jats:italic>FASN<\/jats:italic>\n                    ,\n                    <jats:italic>ACC<\/jats:italic>\n                    , and\n                    <jats:italic>SREBP1<\/jats:italic>\n                    ). Consequently, targeted TFEB mRNA therapy significantly reduced hepatic triglyceride content, attenuated steatosis, lowered MASLD activity scores, and decreased fibrotic remodeling. Mechanistically, transcriptomic profiling, ChIP-qPCR, promoter-reporter assays, and targeted knockdown models indicated that TFEB exerts its protective effects against lipid accumulation at least partly by transcriptionally activating the fibroblast growth factor 21 (FGF21) signaling pathway. Collectively, these findings establish LNP-mediated TFEB mRNA delivery as a useful preclinical approach for investigating hepatic biology and provide a targeted, transient, and non-integrating genetic strategy with potential for the treatment of MASLD.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00615-0","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:30Z","timestamp":1792573290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid nanoparticle-mediated transcription factor EB mRNA delivery for the treatment of metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1186","volume":"7","author":[{"given":"Wenhao","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangpo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng George","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-8010","authenticated-orcid":false,"given":"Haocheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"10","key":"615_CR1","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"issue":"10290","key":"615_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"Lancet"},{"issue":"9","key":"615_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119(9):1787\u201398. https:\/\/doi.org\/10.1093\/cvr\/cvad095.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"615_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","volume":"54","author":"G Sveinbjornsson","year":"2022","unstructured":"Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54(11):1652\u201363. https:\/\/doi.org\/10.1038\/s41588-022-01199-5.","journal-title":"Nat Genet"},{"issue":"5","key":"615_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1053\/j.gastro.2016.01.005","volume":"150","author":"Y Fan","year":"2016","unstructured":"Fan Y, Lu H, Guo Y, Zhu T, Garcia-Barrio MT, Jiang Z, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology. 2016;150(5):1208\u201318. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.005.","journal-title":"Gastroenterology"},{"issue":"5","key":"615_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367\u201393. https:\/\/doi.org\/10.1210\/er.2019-00034.","journal-title":"Endocr Rev"},{"issue":"6","key":"615_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349\u201364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"615_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.106038","volume":"18","author":"AA Alzaki","year":"2026","unstructured":"Alzaki AA, Alqahtani MZ, Aman E, Asiri GM, Al Jibril MH, Desoky R, et al. THR-beta agonists vs incretin therapies for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH): a biopsy-anchored systematic review with Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty. Cureus. 2026;18(3):e106038. https:\/\/doi.org\/10.7759\/cureus.106038.","journal-title":"Cureus"},{"issue":"4","key":"615_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101708","volume":"8","author":"R Dos Santos Borges","year":"2026","unstructured":"Dos Santos Borges R, Abreu ES, Berton GG, de Paula LH, Conegundes AF, Martins JMB, et al. Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: a systematic review and meta-analysis. JHEP Rep. 2026;8(4):101708. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101708.","journal-title":"JHEP Rep"},{"issue":"20","key":"615_CR10","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401397R","volume":"38","author":"JA Inia","year":"2024","unstructured":"Inia JA, Attema J, de Ruiter C, Menke AL, Caspers MPM, Verschuren L, et al. Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-\/-.Leiden mice. FASEB J. 2024;38(20):e70087. https:\/\/doi.org\/10.1096\/fj.202401397R.","journal-title":"FASEB J"},{"key":"615_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103207","volume":"63","author":"H Lu","year":"2021","unstructured":"Lu H, Sun J, Hamblin MH, Chen YE, Fan Y. Transcription factor EB regulates cardiovascular homeostasis. EBioMedicine. 2021;63:103207. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103207.","journal-title":"EBioMedicine"},{"issue":"6036","key":"615_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","volume":"332","author":"C Settembre","year":"2011","unstructured":"Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429\u201333. https:\/\/doi.org\/10.1126\/science.1204592.","journal-title":"Science"},{"issue":"8","key":"615_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41418-022-01028-6","volume":"29","author":"A Tan","year":"2022","unstructured":"Tan A, Prasad R, Lee C, Jho EH. Past, present, and future perspectives of transcription factor EB (TFEB): mechanisms of regulation and association with disease. Cell Death Differ. 2022;29(8):1433\u201349. https:\/\/doi.org\/10.1038\/s41418-022-01028-6.","journal-title":"Cell Death Differ"},{"key":"615_CR14","doi-asserted-by":"publisher","unstructured":"Lu H, Fan Y, Qiao C, Liang W, Hu W, Zhu T, et al. TFEB inhibits endothelial cell inflammation and reduces atherosclerosis. Sci Signal. 2017;10(464):eaah4214. https:\/\/doi.org\/10.1126\/scisignal.aah4214.","DOI":"10.1126\/scisignal.aah4214"},{"issue":"10","key":"615_CR15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/15548627.2018.1490850","volume":"14","author":"H Zhang","year":"2018","unstructured":"Zhang H, Yan S, Khambu B, Ma F, Li Y, Chen X, et al. Dynamic MTORC1-TFEB feedback signaling regulates hepatic autophagy, steatosis and liver injury in long-term nutrient oversupply. Autophagy. 2018;14(10):1779\u201395. https:\/\/doi.org\/10.1080\/15548627.2018.1490850.","journal-title":"Autophagy"},{"key":"615_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176159","volume":"960","author":"D Zhang","year":"2023","unstructured":"Zhang D, Ma Y, Liu J, Wang D, Geng Z, Wen D, et al. Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. Eur J Pharmacol. 2023;960:176159. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176159.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"615_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202200812","volume":"68","author":"L Guan","year":"2024","unstructured":"Guan L, Guo L, Zhang H, Liu H, Zhou W, Zhai Y, et al. Naringin protects against non-alcoholic fatty liver disease by promoting autophagic flux and lipophagy. Mol Nutr Food Res. 2024;68(3):e2200812. https:\/\/doi.org\/10.1002\/mnfr.202200812.","journal-title":"Mol Nutr Food Res"},{"issue":"6","key":"615_CR18","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.apsb.2021.12.012","volume":"12","author":"X Du","year":"2022","unstructured":"Du X, Di Malta C, Fang Z, Shen T, Niu X, Chen M, et al. Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy-lysosomal pathway. Acta Pharm Sin B. 2022;12(6):2869\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2021.12.012.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"615_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","volume":"3","author":"JB Mannick","year":"2023","unstructured":"Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat Aging. 2023;3(6):642\u201360. https:\/\/doi.org\/10.1038\/s43587-023-00416-y.","journal-title":"Nat Aging"},{"issue":"1","key":"615_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94. https:\/\/doi.org\/10.1038\/s41392-022-00950-y.","journal-title":"Signal Transduct Target Ther"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154\u2013155","author":"R Bottger","year":"2020","unstructured":"Bottger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101. https:\/\/doi.org\/10.1016\/j.addr.2020.06.017.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"615_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater. 2023;8(4):282\u2013300. https:\/\/doi.org\/10.1038\/s41578-022-00529-7.","journal-title":"Nat Rev Mater"},{"issue":"6","key":"615_CR23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","volume":"75","author":"T Yang","year":"2021","unstructured":"Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. 2021;75(6):1420\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2021.08.011.","journal-title":"J Hepatol"},{"key":"615_CR24","doi-asserted-by":"publisher","unstructured":"Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 2020;12(572):eaba4448. https:\/\/doi.org\/10.1126\/scitranslmed.aba4448.","DOI":"10.1126\/scitranslmed.aba4448"},{"key":"615_CR25","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1128","volume":"4","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17. https:\/\/doi.org\/10.2202\/1544-6115.1128.","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"6","key":"615_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ncb2718","volume":"15","author":"C Settembre","year":"2013","unstructured":"Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013;15(6):647\u201358. https:\/\/doi.org\/10.1038\/ncb2718.","journal-title":"Nat Cell Biol"},{"key":"615_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155183","volume":"123","author":"Z Shang","year":"2024","unstructured":"Shang Z, Gao Y, Xue Y, Zhang C, Qiu J, Qian Y, et al. Shenge formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1. Phytomedicine. 2024;123:155183. https:\/\/doi.org\/10.1016\/j.phymed.2023.155183.","journal-title":"Phytomedicine"},{"issue":"7","key":"615_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/gutjnl-2016-311408","volume":"65","author":"E Piccinin","year":"2016","unstructured":"Piccinin E, Moschetta A. Hepatic-specific PPARalpha-FGF21 action in NAFLD. Gut. 2016;65(7):1075\u20136. https:\/\/doi.org\/10.1136\/gutjnl-2016-311408.","journal-title":"Gut"},{"issue":"2","key":"615_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543784.2020.1718104","volume":"29","author":"M Ritchie","year":"2020","unstructured":"Ritchie M, Hanouneh IA, Noureddin M, Rolph T, Alkhouri N. Fibroblast growth factor (FGF)-21 based therapies: a magic bullet for nonalcoholic fatty liver disease (NAFLD)? Expert Opin Investig Drugs. 2020;29(2):197\u2013204. https:\/\/doi.org\/10.1080\/13543784.2020.1718104.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"615_CR30","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2812351","volume":"28","author":"Z Wang","year":"2023","unstructured":"Wang Z, Sun T, Yu J, Li S, Gong L, Zhang Y. FGF21: a sharp weapon in the process of exercise to improve NAFLD. Front Biosci (Landmark Ed). 2023;28(12):351. https:\/\/doi.org\/10.31083\/j.fbl2812351.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"8","key":"615_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.molmet.2015.06.001","volume":"4","author":"JS Hansen","year":"2015","unstructured":"Hansen JS, Clemmesen JO, Secher NH, Hoene M, Drescher A, Weigert C, et al. Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol Metab. 2015;4(8):551\u201360. https:\/\/doi.org\/10.1016\/j.molmet.2015.06.001.","journal-title":"Mol Metab"},{"key":"615_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105964","volume":"174","author":"H Zhang","year":"2021","unstructured":"Zhang H, Lu J, Liu H, Guan L, Xu S, Wang Z, et al. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. Pharmacol Res. 2021;174:105964. https:\/\/doi.org\/10.1016\/j.phrs.2021.105964.","journal-title":"Pharmacol Res"},{"issue":"10","key":"615_CR33","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","volume":"13","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim G, Han DH, Lee M, Kim I, Kim B, et al. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy. 2017;13(10):1767\u201381. https:\/\/doi.org\/10.1080\/15548627.2017.1356977.","journal-title":"Autophagy"},{"issue":"12","key":"615_CR34","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63(12):4057\u201363. https:\/\/doi.org\/10.2337\/db14-0595.","journal-title":"Diabetes"},{"issue":"9","key":"615_CR35","doi-asserted-by":"publisher","first-page":"11816","DOI":"10.1096\/fj.202000678R","volume":"34","author":"M Weber","year":"2020","unstructured":"Weber M, Mera P, Casas J, Salvador J, Rodriguez A, Alonso S, et al. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB J. 2020;34(9):11816\u201337. https:\/\/doi.org\/10.1096\/fj.202000678R.","journal-title":"FASEB J"},{"key":"615_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-026-00340-6","author":"D Lan","year":"2026","unstructured":"Lan D, Sun G, Dong Z, Li K, Li S, He X, et al. Activation of PPARgamma and CPT1A Mediates the Hepatoprotective Effect of Ginsenoside CK against NAFLD in Rats. Biol Proced Online. 2026;28(1):30. https:\/\/doi.org\/10.1186\/s12575-026-00340-6.","journal-title":"Biol Proced Online"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00615-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:32Z","timestamp":1792573292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00615-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00615-0","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was approved by the Laboratory Animal Center of the Southern University of Science and Technology, approval no. SUSTech-JY202302074.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"220"}}